RPTX News and Press, Repare Therapeutics Inc. From 02/16/24

The law firm of Kirby McInerney LLP is investigating potential claims against Repare Therapeutics Inc. (“Repare” or the “Company”) (NASDAQ: RPTX ). The investigation concerns whether Repare and/or certain of its officers have violated the federal securities law...

RP-1664 is a Potential First-in-Class, Selective, PLK4 Inhibitor Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s...

2024-02-12 17:45:24 ET More on Repare Therapeutics Seeking Alpha’s Quant Rating on Repare Therapeutics Historical earnings data for Repare Therapeutics Financial information for Repare Therapeutics Read the full article on Seeking Alpha For fur...

2024-02-12 16:57:21 ET Gainers: ZoomInfo Technologies  ( ZI ) +19% . TripAdvisor ( TRIP ) +12% . Ramaco Resources ( METC ) +5% . Veritone ( VERI ) +4% . Regis Corporation ( RGS ) +4% . Losers: G1 Therapeutics ( GTH...

Repare will regain control of its potential best-in-class oral small molecule ATR inhibitor Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, announced today that it will regain global de...

Milestone payment triggered by dosing of the first patient in camonsertib-based arm in Roche’s Phase 2 TAPISTRY platform clinical trial Repare is eligible to receive up to $1.2 billion in potential milestones, plus royalties on global net product sales Repare Therapeutics...

2024-01-16 10:00:59 ET More on Health Care Select Sector SPDR XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tu...

Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today provided a corporate update and highlighted key milestones anticipated in 2024. “We significantly advanced our pipeline in 2023 an...

Collaborative clinical study will investigate a novel combination of lunresertib, Repare’s first-in-class PKMYT1 inhibitor, and Debio 0123, Debiopharm’s potent, brain-penetrant inhibitor of WEE1 Repare Therapeutics Inc. (“Repare” or the “Company”...

RP-1664 demonstrated potent and selective inhibition of PLK4 and synthetic lethality in TRIM37-high tumor cells in preclinical studies RP-3467 demonstrated complete, sustained regressions preclinically in combination with PARPi, and compelling anti-tumor activity in combination with radio...